Under NTEP, a patient diagnosed with drug-resistant TB (MDR-TB) where the isolate is resistant to Rifampicin alone (Rifampicin-resistant TB/RR-TB) with susceptibility to fluoroquinolones should be classified and treated as:

• A XDR-TB and treated with the BPaL regimen
• B Pre-XDR TB treated with conventional long MDR regimen
• C Mono-resistant TB and treated with extended first-line regimen
• D MDR-TB equivalent and eligible for BPaLM or shorter MDR regimen ✓

Explanation

RR-TB is treated as MDR-TB equivalent under NTEP/WHO guidelines; the current preferred regimen is the shorter all-oral 6-month BPaLM regimen (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin) for those susceptible to fluoroquinolones. XDR-TB now refers to MDR/RR-TB with additional resistance to any fluoroquinolone and at least one Group A drug. BPaL (without Moxifloxacin) is for XDR or pre-XDR.

Reference: Park's Textbook of Preventive and Social Medicine, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.